losartan-potassium and Urogenital-Neoplasms

Topics: Calcitonin; Catecholamines; Chorionic Gonadotropin; Erythropoietin; Estrogens; Female; Hormones, Ectopic; Humans; Inappropriate ADH Syndrome; Male; Nonsuppressible Insulin-Like Activity; Paraneoplastic Endocrine Syndromes; Parathyroid Hormone; Placental Hormones; Prostaglandins; Serotonin; Thyrotropin; Urogenital Neoplasms

Autologous blood transfusion has been widely endorsed, because of the adverse effects attributed to homologous blood transfusion. So we employed autologous blood transfusion to avoid homologous blood transfusion in operation of urological malignant patients. We reviewed our experience with autologous blood transfusion in 48 patients.. A total of 48 patients underwent operation with 400 to 1,200 ml preoperative autologous blood donation, in 41 patients with administration of erythropoietin and 7 patients without erythropoietin. The details of operations are radical nephrectomy in 18 cases (2 cases were bilateral), radical nephro-ureterectomy in 2 cases, retroperitoneal lymph node dissection (RPLND) in 2 cases, radical prostatectomy in 12 cases and radical cystectomy in 14 cases.. The volume of surgical blood loss were 381 +/- 522 ml in nephrectomy (1,158 +/- 202 ml in bilateral case), 517 +/- 5 ml in radical nephro-ureterectomy 636 +/- 574 ml in RPLND, 665 +/- 291 ml in radical prostatectomy and 1,123 +/- 417 ml in radical cystectomy. Only three cases needed homologous blood transfusion.. We can avoid homologous blood transfusion in 94% of patients. Autologous blood transfusion is recommended as safe and convenient.

Topics: Adult; Aged; Blood Preservation; Blood Transfusion, Autologous; Erythropoietin; Female; Humans; Lymph Node Excision; Male; Middle Aged; Urogenital Neoplasms; Urologic Surgical Procedures

The bioassay using the polythemic mice demonstrated persistent erythropoietin (Ep) activity in 24 renal carcinoma patients. Eight patients without clinical evidence of renal carcinoma had Ep levels that were slightly higher than those of controls, suggesting the possibility of occult disease. Increased levels of Ep were noted in 5 patients with other genitourinary carcinomas. This selective study reaffirms the value of Ep as a biologic marker in some renal cell cancers, and occasionally in other genitourinary tumors.

Topics: Aged; Animals; Biological Assay; Carcinoma, Renal Cell; Erythropoietin; Female; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred ICR; Middle Aged; Polycythemia; Urogenital Neoplasms